以ABCA1为靶点的补肾中药复方防治动脉粥样硬化的思路探讨  

Discussion on the Idea of ABCA1 as Novel Target for Treatment of Atherosclerosis by Compound Chinese Medicine for Reinforcing Kidney

作　　者：李杉杉[1,2] 申定珠[1,2] 陈川[1,2] 邢三丽[1,2] 

机构地区：[1]上海中医药大学,上海201203 [2]上海市中医老年医学研究所,上海200031

出　　处：《中国中医急症》2017年第5期834-837,共4页Journal of Emergency in Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81373706);上海市自然科学基金项目(16ZR1433900);上海市卫计委科研项目(201640217)

摘　　要：动脉粥样硬化(AS)是心脑血管疾病共同的病理基础,包括脂质代谢紊乱在内的多种因素在AS形成及发展过程中发挥重要作用。胆固醇逆向转运(RCT)指高密度脂蛋白(HDL)将多余胆固醇转运至肝脏再循环或以胆酸形式排出体外的过程。三磷酸腺苷结合盒转运体A1(ABCA1)作为一种整合膜蛋白,可促进细胞内游离胆固醇和磷脂的流出,从而在RCT和HDL生成中发挥关键作用。多种促AS的炎症因子亦可通过下调ABCA1的表达,促进AS的发生、发展。结合补肾中药复方可有效干预治疗AS的前期研究结果。本文拟以ABCA1为靶点进一步探讨补肾中药复方防治AS的研究策略。Atherosclerosis （AS） is the common pathological basis of cardiovascular and cerebrovascular diseases, multiple factors including lipid metabolic disorder play an important role in the process of formation and development of AS. Reverse cholesterol transport （RCT） refers the high density lipoprotein （HDL） take excess cholesrerol to the livevrecirculation, or in the form of cholic acid. As a kind of integrated membrane proteins, ATP Binding Cassette Transporter A1 （ABCA1） can contribute to the outflow of intracellular free cholesterol and lecithin, which plays a key role in the RCT and generation of HDL. Variety of inflammatory factors to promote AS can also be reduced by the expression of ABCA1 ,thus promote the occurrence and development of AS.Combined with compound Chinese medicine for reinforcing kidney can effectively intervene in the treatment of AS prelimi- nary results ,this article intends to ABCAI as a target to further explore the compound Chinese medicine for reinforcing kidney prevention and treatment of AS research strategy.

关 键 词：动脉粥样硬化 胆固醇逆向转运 三磷酸腺苷结合盒转运体 A1 补 肾中药复方 

分 类 号：R543.5[医药卫生—心血管疾病]